![conference banner](/images/conference-banner.jpeg)
Abstract
T helper (Th)17 cells and other interleukin (IL)-17-producing cells are supposed to play critical roles in several human immune-mediated diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), the main forms of inflammatory bowel diseases (IBD) in man. Th17 cells infiltrate massively the inflamed intestine of IBD patients and in vitro and in vivo studies have shown that Th17-type cytokines may trigger and amplify multiple inflammatory pathways. Nonetheless, some Th17-related cytokines, such as interleukin (IL)-17A and IL-22, may target gut epithelial cells and promote the activation of counter-regulatory mechanisms. This observation together with the demonstration that Th17 cells are not stable and can be converted into either regulatory T cells or Th1 cells if stimulated by immune-suppressive (e.g. TGF-β1) or inflammatory (e.g. IL-12, IL-23) cytokines have contributed to advance our understanding of mechanisms that regulate mucosal homeostasis and inflammation in the gut.
Current Molecular Medicine
Title:Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?
Volume: 12 Issue: 5
Author(s): I. Monteleone, M. Sarra, F. Pallone and G. Monteleone
Affiliation:
Abstract: T helper (Th)17 cells and other interleukin (IL)-17-producing cells are supposed to play critical roles in several human immune-mediated diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), the main forms of inflammatory bowel diseases (IBD) in man. Th17 cells infiltrate massively the inflamed intestine of IBD patients and in vitro and in vivo studies have shown that Th17-type cytokines may trigger and amplify multiple inflammatory pathways. Nonetheless, some Th17-related cytokines, such as interleukin (IL)-17A and IL-22, may target gut epithelial cells and promote the activation of counter-regulatory mechanisms. This observation together with the demonstration that Th17 cells are not stable and can be converted into either regulatory T cells or Th1 cells if stimulated by immune-suppressive (e.g. TGF-β1) or inflammatory (e.g. IL-12, IL-23) cytokines have contributed to advance our understanding of mechanisms that regulate mucosal homeostasis and inflammation in the gut.
Export Options
About this article
Cite this article as:
Monteleone I., Sarra M., Pallone F. and Monteleone G., Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?, Current Molecular Medicine 2012; 12 (5) . https://dx.doi.org/10.2174/156652412800620066
DOI https://dx.doi.org/10.2174/156652412800620066 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Matrix Metalloproteinases
Current Medicinal Chemistry Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Mast Cells as a Double Edged Sword in Immunity: Disorders of Mast Cell Activation and Therapeutic Management. Second of Two Parts
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Plasticity of Neuroendocrine-Immune Interactions During Ontogeny: Role of Perinatal Programming in Pathogenesis of Inflammation and Stress- Related Diseases in Adults
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy Probiotics as an Adjuvant Therapy in Major Depressive Disorder
Current Neuropharmacology Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design